secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-07-31T12:23:43+00:00
Accession:  0001104659-26-089008
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon furnishes supplemental non-GAAP Q2 2026 metrics; merger with Sun Pharma pending
--------------------------------------------------------------------------------

- Company released Q2 2026 financial results via Form 10-Q, not a press release, due to pending merger with Sun Pharmaceutical Industries.
- Supplemental non-GAAP metrics for Q2 2026 are furnished in Exhibit 99.1 but no specific figures are provided in the filing text.
- Customary earnings press release and conference call suspended for the quarter.
- Non-GAAP measures are intended to supplement GAAP results; full GAAP disclosures are in the 10-Q filed July 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/0001104659-26-089008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/tm2621744d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-089008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer